CD274 and neoplasm: The IMVigor 210 trial, a phase II multicenter non-randomized study, was groundbreaking in demonstrating the efficacy and safety of atezolizumab for treating urothelial cancer [31]. In this study, 119 patients who were ineligible for cisplatin-based chemotherapy had an overall response rate (ORR) of 24%, observed across all subgroups of PD-L1 in tumor-infiltrating immune cells.